Download PDF
1 / Pages

Other users also viewed these articles

SEA 2022 standards for the comprehensive control of cardiovascular risk J.M. Mostaza; X. Pintó; P. Armario; L. Masana; J.T. Real; P. Valdivielso; T. Arrobas-Velilla; R. Baeza-Trinidad; P. Calmarza; J. Cebollada; M. Civera-Andrés; J.I. Cuende Melero; J.L. Díaz-Díaz; J. Fernández Pardo; C. Guijarro; C. Jericó; M. Laclaustra; C. Lahoz; J. López-Miranda; S. Martínez-Hervás; O. Muñiz-Grijalvo; J.A. Páramo; V. Pascual; J. Pedro-Botet; P. Pérez-Martínez; N. Plana; J. Puzo; M.Á. Sánchez Chaparro; L. Vila;
Clin Investig Arterioscler. 2022;34:130-79
Observational study of patients from a Lipid Unit on lipid-modifying therapy for primary and secondary prevention: ULFI Study Àlex Vila; Estel Pons; Patricia Trinidad García; Daniel Vidal; Sara López; Armand Grau;
Clin Investig Arterioscler. 2023;35:272-9
Prevalence of atherogenic dyslipidemia, related factors and level of lipid control in the general population of Galicia. GALIPEMIAS study Carlos Názara; Rosa M. Argüeso; Juan Pedro-Botet; Xavier Pintó; Jesús Millán; Marta Pena Seijo; Pablo A. Fernández; M. Eugenia Ameneiros; Alberto del Alamo; Avelino Rodríguez; José Antonio Díaz-Peromingo; María Rosa Vázquez Freire; Javier Muñiz; Teresa R. Pérez-Castro; José Luis Díaz-Díaz; Antonio Pose Reino;
Clin Investig Arterioscler. 2023;35:178-84